Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure
المؤلفون المشاركون
Abo-amer, Yousry Esam-Eldin
Badawi, Rehab
El-Abgeegy, Mohamed
Elsergany, Heba Fadl
Mohamed, Ahmed Abdelhaleem
Mostafa, Sahar Mohamed
Alegaily, Hatem Samir
Soliman, Shaimaa
Elnawasany, Sally
Abd-Elsalam, Sherief
المصدر
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-07-24
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Background and Aims.
Direct-acting antivirals (DAAs) have made a revolution in hepatitis C virus (HCV) treatment with promising reduction of HCV infection and disease morbidities.
However, unfortunately, treatment failure still occurs in about 5–15% of patients treated with DAA‐based combination regimens.
The primary aim of the study was to assess the efficacy and safety of a quadruple regimen of (sofosbuvir, daclatasvir, and simeprevir with a weight-based ribavirin) in chronic HCV DAAs-experienced patients.
Methods.
This observational, open-label prospective study was carried out on 103 genotype 4 hepatitis C virus-infected patients who failed to achieve SVR12 after sofosbuvir-daclatasvir with or without ribavirin.
Patients were treated for three months with sofosbuvir (400 mg), daclatasvir (60 mg), and simeprevir (150 mg) with a weight-based ribavirin dosage (1000–1200 mg/d).
Response to treatment was determined by quantitative PCR for HCV at 3 months after the end of treatment (SVR12), and adverse events during the treatment were recorded.
Results.
SVR was achieved in 100 patients (97.1%) at week 12 after treatment.
No dangerous or life-threatening adverse events were recorded.
Conclusions.
Retreatment of HCV genotype 4 patients with quadruple therapy is a good therapeutic option and achieves high response rates with minimal side effects.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Abo-amer, Yousry Esam-Eldin& Badawi, Rehab& El-Abgeegy, Mohamed& Elsergany, Heba Fadl& Mohamed, Ahmed Abdelhaleem& Mostafa, Sahar Mohamed…[et al.]. 2020. Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure. Advances in Virology،Vol. 2020, no. 2020, pp.1-6.
https://search.emarefa.net/detail/BIM-1130691
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Abo-amer, Yousry Esam-Eldin…[et al.]. Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure. Advances in Virology No. 2020 (2020), pp.1-6.
https://search.emarefa.net/detail/BIM-1130691
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Abo-amer, Yousry Esam-Eldin& Badawi, Rehab& El-Abgeegy, Mohamed& Elsergany, Heba Fadl& Mohamed, Ahmed Abdelhaleem& Mostafa, Sahar Mohamed…[et al.]. Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure. Advances in Virology. 2020. Vol. 2020, no. 2020, pp.1-6.
https://search.emarefa.net/detail/BIM-1130691
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1130691
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر